Full-Time

Legal Counsel

Remote

Posted on 9/9/2026

Prime Therapeutics

Prime Therapeutics

1,001-5,000 employees

Pharmacy benefits management and drug programs

Compensation Overview

$124k - $211k/yr

No H1B Sponsorship

Remote in USA

Remote

JD

Category
Legal (1)
Required Skills
CAD

Get referred to Prime Therapeutics

See people who can refer or advise you

Requirements
  • Juris Doctor degree.
  • Current license to practice law in at least one United States jurisdiction.
  • At least 5 years of experience practicing as an attorney or in a related legal experience in a regulatory or compliance role, including at least 3 years working with managed care companies or other health care clients.
  • Must be eligible to work in the United States without the need for work visa or residency sponsorship.
  • Strong transactional skills, including drafting and negotiating complex commercial agreements.
  • Ability to successfully manage multiple tasks with competing priorities.
  • Ability to establish rapport and build relationships among all levels of the organization.
  • Demonstrated ability to distill complex concepts or situations into concise and compelling communications.
  • Expert communication and influencing skills.
Responsibilities
  • Provide tactical legal advice and support to internal clients, including PBM, pharmacy, specialty pharmacy, government programs, administrative support functions, or other assigned areas.
  • Perform research, drafting, and transactional work in support of legal matters, with a focus on client-facing contracting and support of account management functions.
  • Advise internal clients regarding compliance with regulatory requirements and corporate policies; develop and facilitate legal training and investigate issues as needed.
  • Provide client training on legal principles.
  • Coordinate partnerships with in-house and outside legal resources where appropriate.
  • Perform other assigned duties.
Desired Qualifications
  • Experience with pharmacy benefit managers, pharmacies and/or health benefit insurers.

Prime Therapeutics provides pharmacy benefit management, specialty and medical drug management, and state government drug solutions for millions of people. It helps health plans and government programs control drug benefits by negotiating discounts, designing formularies, processing claims, and overseeing utilization to ensure safe and appropriate use of medications. It combines traditional PBM services with specialty and medical drug programs and a focus on government solutions to serve both private and public payers. Its goal is to deliver savings, simplicity, and support that help people achieve better health.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Eagan, Minnesota

Founded

1987

Get referred to Prime Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Prime and Sempre expanded nationwide after 19,500 enrollments and $4.7 million savings.
  • Blue Cross NC reported 15-point adherence gains and a 98 Net Promoter Score.
  • Prime won 2025 AMCP awards for GLP-1 and prior-authorization research, strengthening employer credibility.

What critics are saying

  • Michigan sued Prime on April 29, 2025, alleging anticompetitive pharmacy reimbursement suppression.
  • That suit seeks to unwind Prime’s Express Scripts pact, risking network disruption by 2026.
  • PBM margin compression and antitrust scrutiny threaten Prime’s core economics and employer relationships.

What makes Prime Therapeutics unique

  • Prime Therapeutics has about 10.3% PBM share, behind CVS, OptumRx, Express Scripts.
  • Its Sempre Health model ties copay discounts to adherence, boosting chronic-drug persistence.
  • Prime’s GLP-1 research positions it as a data-heavy PBM, not just a middleman.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Company News

PYMNTS
Aug 27th, 2026
Florida sues Prime Therapeutics, Express Scripts over alleged price fixing.

Florida sues Prime Therapeutics, Express Scripts over alleged price fixing. By CPI | August 27, 2026 Florida's attorney general sued Prime Therapeutics and Express Scripts, accusing the pharmacy benefit managers of coordinating reimbursement rates in a way that squeezed local pharmacies and potentially reduced patients' access to prescription drugs. Florida Attorney General James Uthmeier announced the lawsuit Thursday in The Villages, according to FOX 35 Orlando. The state alleges the companies violated Florida antitrust and consumer-protection laws through an arrangement that lowered payments made to pharmacies for dispensing prescription medications. The case adds to mounting scrutiny of pharmacy benefit managers, or PBMs, the intermediaries that negotiate drug benefits and determine reimbursement terms for pharmacies. Independent drugstores have increasingly argued that reimbursement practices can leave them dispensing some prescriptions at a loss. Florida's complaint alleges that Prime and Express Scripts reached an agreement in December 2019 under which Prime adopted lower reimbursement rates associated with Express Scripts. The arrangement took effect in April 2020, has since been extended several times and remains in place, according to the lawsuit as reported by FOX 35 Orlando. The state alleges the changes produced steep reductions in pharmacy reimbursements. Payments for brand-name medications fell as much as 80%, while those for generic drugs declined as much as 70%, according to the complaint cited by FOX 35. Florida contends the resulting rates sometimes required local pharmacies to fill prescriptions for less than their costs. Please add Competition Policy International to your preferred sources list so its news, data and interviews show up in your feed. Thanks! Uthmeier said the alleged conduct threatens both independent pharmacies and consumers who rely on them, particularly seniors and families. He accused the companies of coordinating prices and underpaying pharmacies, saying closures can leave patients with fewer options for obtaining medicines, according to FOX 35. Prime disputed the state's characterization. In a statement provided to FOX 35, the company said the lawsuit places too much emphasis on pharmacy profitability while failing to account for the costs ultimately borne by patients, employers, health plans and taxpayers. Prime said its approach has reduced consumers' pharmacy-counter costs and generated savings while preserving broad pharmacy access. Evernorth, the parent of Express Scripts, also rejected Florida's claims. The company called the allegations baseless and said it reimburses pharmacies fairly and intends to defend itself vigorously, according to FOX 35. Florida's lawsuit includes claims of conspiracy in restraint of trade under the state's antitrust law, conduct allegedly violating the Florida Deceptive and Unfair Trade Practices Act, and unjust enrichment. The attorney general is seeking an injunction, civil penalties, damages exceeding $50,000 and a jury trial, FOX 35 reported, citing the complaint. The action follows broader pressure in Florida on the business practices of PBMs. Uthmeier's office announced an investigation in June into CVS Health and its Caremark pharmacy-benefit operation over concerns involving competition, reimbursement practices and the treatment of independent pharmacies, according to a separate FOX 35 report. The latest case shifts that scrutiny into litigation against two other major industry participants. Its outcome could help determine how far Florida can use state antitrust and consumer-protection statutes to challenge the reimbursement arrangements that sit between health plans, benefit managers and neighborhood pharmacies. FOX 35 said its reporting was based on Uthmeier's Aug. 27 announcement in The Villages, the lawsuit released afterward and responses the station obtained from Prime Therapeutics and Evernorth/Express Scripts. Iowa, Montana ask Supreme Court to halt Paramount merger challenge. By CPI | August 27, 2026 Iowa and Montana have asked the U.S. Supreme Court to intervene in a multistate antitrust challenge to Paramount Skydance Corp.'s planned acquisition of Warner Bros. Discovery, arguing that the litigation threatens a transaction they say would benefit consumers and the broader economy. The two states are seeking to stop California and other state attorneys general from pursuing their case against the combination, according to Law360, which reported on the Supreme Court filing Wednesday. Iowa and Montana characterize the opposing states' lawsuit as politically driven and contend that the transaction is procompetitive. The unusual Supreme Court request adds another layer of state-level conflict to a major media transaction already facing an antitrust fight. Law360 reported that the dispute involves Paramount Skydance's proposed purchase of Warner Bros. Discovery, whose assets include Warner Bros. and CNN. Rather than simply joining the existing litigation on the side of the companies, Iowa and Montana are asking the justices to exercise the Supreme Court's authority over disputes between states. Their position is that the states challenging the transaction are using antitrust enforcement in a way that harms the economic interests of residents outside their borders. According to the filing described by Law360, Iowa and Montana maintain that the opposing attorneys general are attempting to use the courts to block a lawful media transaction for political reasons. They are seeking declaratory and injunctive relief that would prevent those states from obtaining an order stopping the merger. Please add Competition Policy International to your preferred sources list so its news, data and interviews show up in your feed. Thanks! The filing places competing views of state antitrust authority before the nation's highest court. California and its partners are pursuing their challenge on competition grounds, while Iowa and Montana argue that one group of states should not effectively determine national economic policy for other states by blocking an interstate transaction. The underlying litigation has already produced a significant setback for the companies. A federal judge in California granted temporary relief against the transaction in July, leaving the antitrust dispute headed toward further proceedings. The Supreme Court filing also underscores the increasingly complicated legal landscape surrounding large media combinations. State attorneys general can pursue antitrust claims independently of federal enforcement agencies, creating the possibility that transactions can face challenges even when other government authorities take a different view of their competitive effects. Law360 identified the U.S. Department of Justice, the California Attorney General's Office and the Iowa Attorney General's Office among the government agencies connected to the dispute. The publication also identified Paramount-related Skydance Media, Warner Bros. Discovery, Warner Bros., CNN and Netflix among companies relevant to its coverage. The Supreme Court has not yet resolved Iowa and Montana's request. The filing means the justices must first confront whether the dispute is one the court should hear directly before reaching the broader disagreement over the merger and the authority of states seeking to block it.

PYMNTS
Aug 27th, 2026
Poland seeks €250 million EU fine against Meta over scam ads.

Poland seeks €250 million EU fine against Meta over scam ads. By CPI | August 27, 2026 Poland is pressing European Union regulators to impose a €250 million ($291 million) penalty on Meta Platforms Inc., escalating scrutiny of the social-media company over allegations that it has failed to adequately remove fraudulent advertisements. Polish Digital Affairs Minister Krzysztof Gawkowski asked the European Commission to levy the fine, arguing that Meta's response to scam advertising has remained insufficient despite repeated notifications from Polish authorities and cybersecurity specialists, according to Reuters. The request adds to regulatory and legal pressure facing Meta over how it polices content and protects users across Facebook and Instagram. Poland's complaint centers on advertisements that authorities classified as fraudulent and the company's handling of reports seeking their removal. In a letter to the European Commission, Gawkowski cited testing by CERT Polska, Poland's national cybersecurity incident-response team. The organization identified 122 advertisements it considered fraudulent, Reuters reported. Meta declined to remove 106 of those ads, representing 86.8% of the reports, according to figures provided by the minister. Ten were taken down and six reports received no response. Gawkowski said Meta's response showed that stronger enforcement was necessary and called for tools capable of more effectively identifying and eliminating scams, misleading advertisements and promotions for illegal applications, according to Reuters. Please add Competition Policy International to your preferred sources list so its news, data and interviews show up in your feed. Thanks! The proposed €250 million penalty would mark a significant escalation in Poland's effort to hold the technology company accountable for advertising distributed through its platforms. Gawkowski has argued that the size of Meta's business and the harm allegedly suffered by Polish users warrant a financial sanction large enough to have a deterrent effect, Reuters reported. Meta has said it is investing in technology and partnerships with industry groups and law-enforcement agencies to combat increasingly sophisticated online fraud, according to Reuters. The company has characterized scammers as persistent operators whose methods continue to evolve. The dispute also follows litigation in Poland involving billionaire Rafal Brzoska, who sued Meta in 2024 after fraudulent advertisements on Facebook and Instagram allegedly used his image and circulated false claims concerning his wife, according to Reuters. A Warsaw appeals court ruled in April 2026 that Meta could be held responsible for advertisements hosted on its platforms. Meta had argued that it should not bear responsibility for fraudulent conduct by its users. Poland's push comes as Meta faces broader scrutiny over the operation and safety of its social networks. Reuters reported that the company has also faced allegations in the US concerning the effects of its products on children. Gawkowski is seeking to turn the Polish dispute into a broader European issue. He said he plans to urge European leaders at the upcoming Group of 20 summit to take a coordinated position on Meta's practices, according to Reuters. The decision on whether to pursue the requested penalty rests with European authorities. Poland's intervention nevertheless raises the stakes for Meta as governments increasingly focus on whether large online platforms are doing enough to prevent fraudulent advertising from reaching consumers. Florida sues Prime Therapeutics, Express Scripts over alleged price fixing. By CPI | August 27, 2026 Florida's attorney general sued Prime Therapeutics and Express Scripts, accusing the pharmacy benefit managers of coordinating reimbursement rates in a way that squeezed local pharmacies and potentially reduced patients' access to prescription drugs. Florida Attorney General James Uthmeier announced the lawsuit Thursday in The Villages, according to FOX 35 Orlando. The state alleges the companies violated Florida antitrust and consumer-protection laws through an arrangement that lowered payments made to pharmacies for dispensing prescription medications. The case adds to mounting scrutiny of pharmacy benefit managers, or PBMs, the intermediaries that negotiate drug benefits and determine reimbursement terms for pharmacies. Independent drugstores have increasingly argued that reimbursement practices can leave them dispensing some prescriptions at a loss. Florida's complaint alleges that Prime and Express Scripts reached an agreement in December 2019 under which Prime adopted lower reimbursement rates associated with Express Scripts. The arrangement took effect in April 2020, has since been extended several times and remains in place, according to the lawsuit as reported by FOX 35 Orlando. The state alleges the changes produced steep reductions in pharmacy reimbursements. Payments for brand-name medications fell as much as 80%, while those for generic drugs declined as much as 70%, according to the complaint cited by FOX 35. Florida contends the resulting rates sometimes required local pharmacies to fill prescriptions for less than their costs. Please add Competition Policy International to your preferred sources list so its news, data and interviews show up in your feed. Thanks! Uthmeier said the alleged conduct threatens both independent pharmacies and consumers who rely on them, particularly seniors and families. He accused the companies of coordinating prices and underpaying pharmacies, saying closures can leave patients with fewer options for obtaining medicines, according to FOX 35. Prime disputed the state's characterization. In a statement provided to FOX 35, the company said the lawsuit places too much emphasis on pharmacy profitability while failing to account for the costs ultimately borne by patients, employers, health plans and taxpayers. Prime said its approach has reduced consumers' pharmacy-counter costs and generated savings while preserving broad pharmacy access. Evernorth, the parent of Express Scripts, also rejected Florida's claims. The company called the allegations baseless and said it reimburses pharmacies fairly and intends to defend itself vigorously, according to FOX 35. Florida's lawsuit includes claims of conspiracy in restraint of trade under the state's antitrust law, conduct allegedly violating the Florida Deceptive and Unfair Trade Practices Act, and unjust enrichment. The attorney general is seeking an injunction, civil penalties, damages exceeding $50,000 and a jury trial, FOX 35 reported, citing the complaint. The action follows broader pressure in Florida on the business practices of PBMs. Uthmeier's office announced an investigation in June into CVS Health and its Caremark pharmacy-benefit operation over concerns involving competition, reimbursement practices and the treatment of independent pharmacies, according to a separate FOX 35 report. The latest case shifts that scrutiny into litigation against two other major industry participants. Its outcome could help determine how far Florida can use state antitrust and consumer-protection statutes to challenge the reimbursement arrangements that sit between health plans, benefit managers and neighborhood pharmacies. FOX 35 said its reporting was based on Uthmeier's Aug. 27 announcement in The Villages, the lawsuit released afterward and responses the station obtained from Prime Therapeutics and Evernorth/Express Scripts.

My Florida Legal
Aug 27th, 2026
Attorney General James Uthmeier takes legal action against Prime Therapeutics and Express Scripts for price-fixing scheme threatening Floridians' access to affordable medications.

Attorney General James Uthmeier takes legal action against Prime Therapeutics and Express Scripts for price-fixing scheme threatening Floridians' access to affordable medications. Release Date Aug 27, 2026 Communications (850) 245-0150 Courtesy of the Office of the Attorney General TALLAHASSEE, Fla. - Attorney General James Uthmeier filed a lawsuit against Prime Therapeutics LLC and Express Scripts, Inc., alleging the two competing pharmacy benefit managers entered into an illegal horizontal price-fixing agreement that threatens Floridians' access to affordable medications. "Floridians - especially our seniors and families - depend on local pharmacies for the medications that keep them healthy," said Attorney General James Uthmeier. "Prime and Express Scripts colluded to fix prices and underpay those pharmacies, forcing many to fill prescriptions at a loss. When pharmacies struggle or close, patients lose local options and access to care. My office is holding them accountable to protect Florida patients." According to the complaint filed in the Circuit Court of the Tenth Judicial Circuit in and for Polk County, the competitors announced a "collaboration" in December 2019 under which Prime adopted Express Scripts' significantly lower reimbursement rates. The agreement took effect in April 2020, has been extended multiple times, and remains in effect today. Prior to the deal, Prime's reimbursement rates were roughly 20% higher. Afterward, reimbursement rates declined for around 80% of branded drugs and 70% of generic drugs, turning many prescriptions into losses for the pharmacies patients rely on. These cuts jeopardize pharmacies' ability to serve their communities. For example, a pharmacy outside Orlando saw its reimbursement for one drug drop 45%, turning a profit into a $15.45 loss per prescription - increasing the risk that Floridians will face fewer local options for critical medications. Prime valued the first three years of the arrangement at $2.5 billion in "cost savings" extracted from those pharmacies. The lawsuit alleges a per se violation of the Florida Antitrust Act as horizontal price-fixing, as well as unfair methods of competition under the Florida Deceptive and Unfair Trade Practices Act. The Attorney General seeks injunctive relief, civil penalties, disgorgement, damages, and other remedies to stop the ongoing harm and protect patients' access to care. This action reinforces Attorney General Uthmeier's commitment to enforcing Florida's antitrust and consumer protection laws, promoting fair competition, and protecting Floridians' access to the local pharmacies and essential, affordable medications they depend on every day.

Fox Business
Aug 13th, 2026
Nine major PBMs to display TrumpRx prescription drug prices from 2027

Nine pharmacy benefit managers will integrate TrumpRx prescription drug pricing into their benefit tools, effective 1 January 2027. The Pharmaceutical Care Management Association and participating PBMs—including CVS Health, Express Scripts, Humana, and OptumRx—will display cash prices from TrumpRx alongside plan coverage costs. The agreement covers commercial, Medicare, and Medicaid plans. Patients will see TrumpRx prices for all listed drugs, whether through presidential deals or standard pricing. CMS Administrator Dr Mehmet Oz said the commitment will help patients compare prices and find better deals. PCMA CEO David Marin stated the transparency will allow consumers to make better-informed choices about prescription drug costs. Some PBMs will use Real Time Benefit Tools to display pricing comparisons, whilst others may employ different methods.

Prime Therapeutics
Jun 9th, 2026
Managed Healthcare Executive recognizes Prime's Zach Jones as a 2026 Emerging Leader in Healthcare.

Managed Healthcare Executive recognizes Prime's Zach Jones as a 2026 Emerging Leader in Healthcare. Prime Therapeutics employee recognized for contributions to managed care pharmacy and work addressing affordability, access and operational complexity in the healthcare system. by Prime Therapeutics June 09, 2026 Managed Healthcare Executive recently named Zach Jones, PharmD, of Prime Therapeutics (Prime), a 2026 Emerging Leader in Healthcare, recognizing his contributions to managed care pharmacy and his work addressing affordability, access and operational complexity in the healthcare system. The annual Emerging Leaders in Healthcare program highlights professionals selected by Managed Healthcare Executive editors based on peer and colleague nominations. According to the publication, the recognition is designed to spotlight professionals early in their careers who demonstrate measurable achievements and are preparing to take on larger leadership roles across U.S. healthcare. As part of the publication's 2026 Emerging Leaders coverage, Johnson is described as a leader focused on translating complex clinical evidence into practical strategies that help manage specialty pharmacy trend, improve affordability and simplify operations. "For me, it comes down to using clinical evidence in ways that are practical, thoughtful and useful for plans and members," Jones said. In his interview with the publication, Jones reflected on a professional journey shaped by both his Minnesota roots and formative experiences in nontraditional pharmacy settings. He earned both his bachelor's degree in pharmaceutical sciences and his PharmD from North Dakota State University, then began his career in retail pharmacy before moving into managed care through a residency at HealthPartners. "The most impactful turning point in my career was in my final year of pharmacy school," Jones said in his interview. "I intentionally sought out rotations in non-traditional settings to explore paths beyond hospital and retail practice." He said rotations at Eli Lilly and HealthPartners helped define his path and showed him how clinical insight could be applied to population-level drug management decisions, which ultimately led him toward managed care pharmacy. At Prime, Jones's work has also been recognized internally for its cross-functional impact. Colleagues nominated him for being a strategic leader who helps align clinical, operational and client-facing teams around formulary approaches intended to improve cost performance while maintaining access, clinical appropriateness and quality outcomes. Read Jones' profile and watch his video interview in the online feature and look for the full list of honorees in Managed Healthcare Executive's June print issue. About Prime Therapeutics. Prime Therapeutics LLC (Prime) is a diversified pharmacy solutions organization. Prime Therapeutics offer innovative pharmacy benefit management, specialty and medical drug management, and state government solutions to millions of people across the country. At Prime, Prime Therapeutics is reimagining pharmacy solutions to provide the care Prime Therapeutics'd want for its loved ones. Prime Therapeutics challenge the way it's always been done to develop intelligently designed solutions that deliver savings, simplicity and support to help people achieve better health. For more information, visit Prime Therapeutics at PrimeTherapeutics.com or follow Prime Therapeutics on LinkedIn.